Literature DB >> 12145053

A second-generation blood substitute (perflubron emulsion) increases the blood solubility of modern volatile anesthetics in vitro.

Olivier Y Cuignet1, Philippe M Baele, Luc J Van Obbergh.   

Abstract

UNLABELLED: Perfluorocarbon-based emulsions increase the blood solubility of isoflurane, enflurane, and halothane, with a maximal effect reported for the less soluble isoflurane. Current volatile anesthetics are less soluble and may be more affected by this phenomenon. Perflubron (Oxygent(TM)) is a perfluorocarbon-based emulsion in late-stage clinical testing in surgical patients for use as a temporary oxygen carrier. We tested the hypothesis that perflubron increases the solubility of isoflurane, sevoflurane, and desflurane, as reflected by their blood/gas partition coefficient (lambda(Bl:g)). Fresh whole-blood samples were drawn from eight volunteers and mixed with perflubron to obtain concentrations of 1.2%, 1.8%, and 3.6% by volume (equivalent to in vivo doses of 1.8 to 5.4 g/kg, which represent up to twice the intended clinical dose range). By using the double-extraction method, we demonstrated increased lambda(Bl:g) for isoflurane, sevoflurane, and desflurane. However, the solubility in blood does not really change, because volatile anesthetics are actually partitioning into perflubron. Increasing the amount of emulsion in the blood consequently increases the amount of gas carried, as reflected by the measured linear correlation between the lambda(Bl:g) values of all three volatile anesthetics and perflubron doses. Even though the increase ranges from 0.9 (desflurane) to 2.6 (sevoflurane) times the normal value, the apparent lack of clinical implications in current trials with perflubron may trigger further in vivo experiments. IMPLICATIONS: Perflubron increases the in vitro solubility of volatile anesthetics when present in the blood at clinically relevant concentrations. Volatile anesthetics actually partition into the emulsion, but the solubility in the blood does not change. Further studies are needed to assess whether perflubron will affect the pharmacokinetics of volatile anesthetics in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145053     DOI: 10.1097/00000539-200208000-00023

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  In vitro and in vivo assessment of controlled release and degradation of acoustically responsive scaffolds.

Authors:  Alexander Moncion; Keith J Arlotta; Eric G O'Neill; Melissa Lin; Lily A Mohr; Renny T Franceschi; Oliver D Kripfgans; Andrew J Putnam; Mario L Fabiilli
Journal:  Acta Biomater       Date:  2016-09-27       Impact factor: 8.947

2.  Controlled release of basic fibroblast growth factor for angiogenesis using acoustically-responsive scaffolds.

Authors:  Alexander Moncion; Melissa Lin; Eric G O'Neill; Renny T Franceschi; Oliver D Kripfgans; Andrew J Putnam; Mario L Fabiilli
Journal:  Biomaterials       Date:  2017-06-09       Impact factor: 12.479

Review 3.  Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.

Authors:  Pedro Cabrales; Marcos Intaglietta
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

4.  Exceptionally stable fluorous emulsions for the intravenous delivery of volatile general anesthetics.

Authors:  Jun-Pil Jee; Maria C Parlato; Mark G Perkins; Sandro Mecozzi; Robert A Pearce
Journal:  Anesthesiology       Date:  2012-03       Impact factor: 7.892

5.  Fluoropolymer-based emulsions for the intravenous delivery of sevoflurane.

Authors:  Jonathan P Fast; Mark G Perkins; Robert A Pearce; Sandro Mecozzi
Journal:  Anesthesiology       Date:  2008-10       Impact factor: 7.892

6.  Laser activatable perfluorocarbon bubbles for imaging and therapy through enhanced absorption from coupled silica coated gold nanoparticles.

Authors:  Donald A Fernandes; Sila Appak-Baskoy; Elizabeth Berndl; Michael C Kolios
Journal:  RSC Adv       Date:  2021-01-29       Impact factor: 3.361

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.